



Quito, April 11, 2025

Dear WHO Expert Committee Members,

I am Isabel Jaramillo, pediatric hemato – oncologist from Quito, Ecuador. Currently I work at Solca Quito Hospital. In our pediatric department we attend Acute Leukemic pediatric patients with protocol **POLA (Pediatric Oncology Latin America) A TREATMENT GUIDELINE FOR PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA IN BOLIVIA, ECUADOR, PARAGUAY, PERU, AND VENEZUELA**. I have a particular patient case, a girl 13 years old who was diagnosed with High Risk B Acute Lymphoblastic Leukemia, that has not achieved remission

As a pediatric hematologist oncologist, I have seen firsthand the impact of B-cell acute lymphoblastic leukemia in children— particularly in settings where access to innovative therapies is limited. Blinatumomab offers a highly effective, targeted option for these patients and has transformed outcomes in high-income countries.

I believe that having the drug could make a difference for our patients because they will have less serious life complications, less transfusional requirements, better overall survival rates and, the most important thing: better and prolonged complete remission rates.

On behalf of my hospital and department of pediatric onco-hematology, I strongly support this application and urge the Committee to approve blinatumomab for our particular patient.

Sincerely,

Md. Isabel Jaramillo
Pediatric Hemato – oncologist
Hospital SOLCA de Quito, Ecuador
email: isabel.jaramillo@solcaquito.org.ec
telf: +59383845482

Md. Henry Caballero
Medical Director
Hospital SOLCA de Quito, Ecuador
email: dmedica@solcaquito.org.ec
telf: +593992947646